Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eldelumab

Drug Profile

Eldelumab

Alternative Names: Anti-CXCL10 antibody; Anti-IP10 antibody; BMS-936557; MDX-1100

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex
  • Developer Bristol-Myers Squibb; Medarex
  • Class Antirheumatics; Antiulcers; Monoclonal antibodies
  • Mechanism of Action Chemokine CXCL10 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Crohn's disease; Ulcerative colitis
  • Discontinued Multiple sclerosis; Rheumatoid arthritis; Spinal cord injuries

Most Recent Events

  • 04 Oct 2015 No recent reports of development identified - Phase-II for Ulcerative colitis in Russia, Ukraine, Poland, Romania, Mexico, Latvia, Mexico, Czech Republic, France, Netherlands, Hungary, Germany, Italy, Belgium, South Africa, Canada, Australia, Brazil, Austria, USA (IV)
  • 04 Oct 2015 No recent reports of development identified - Phase-II for Crohn's disease (Treatment-experienced) in Poland, Israel, France, Belgium, Hungary, USA, Puerto Rico and South Africa (IV)
  • 01 Dec 2014 Bristol-Myers Squibb completes a phase II trial in Crohn's disease in USA, Belgium, France, Hungary, Israel, Poland, Puerto Rico and South Africa (NCT01466374)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top